Salute e Benessere

LILYSILK Debuts Capsule Collection Made with Liberty Fabrics, Blending British…

LILYSILK's collaboration with Liberty Fabrics unites two brands known for elevating everyday elegance through craftsmanship and design. Since 2010, LILYSILK has championed refined living with premium mulberry silk, while Liberty—renowned since 1875—brings its iconic hand-drawn prints from Soho to life at its Italian mill near Lake Como. LILYSILK's collaboration with Liberty Fabrics unites two brands known for elevating everyday elegance through craftsmanship and design. Since 2010, LILYSILK…
PR Newswire
16/05/2025

Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market…

Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the Union's strategic resilience and autonomy, promote economic growth, and strengthen the sustainability of national healthcare systems. Europe is facing shortages of medicines, with dependence on the supply of key pharmaceutical ingredients from Asia reaching 80%. Restoring essential medicine production is vital to Europe's...
Nasdaq GlobeNewswire
16/05/2025

Lars Rebien Sørensen to join the board of directors of Novo Nordisk A/S

Lars Rebien Sørensen has extensive, first-hand experience of the pharmaceutical industry and the environments in which it operates. From 2000-2016, he was President & CEO of Novo Nordisk A/S, and his current board positions include Ferring Pharmaceuticals, where he has been Vice-Chair since 2023 and also served as Chair from 2021-2023. Lars Rebien Sørensen has extensive, first-hand experience of the pharmaceutical industry and the environments in which it operates. From 2000-2016, he was...
PR Newswire
16/05/2025

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Bagsværd, Denmark, 16 May 2025– Novo Nordisk today announced changes to its executive leadership and Board of Directors.As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. He will continue as CEO for a period to support a smooth transition to new leadership. A search for Lars Fruergaard Jørgensen's successor is ongoing, and an announcement will be made in due course. In connection with the change, Lars Rebien...
Nasdaq GlobeNewswire
16/05/2025

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Bagsværd, Denmark, 16 May 2025– Novo Nordisk today announced changes to its executive leadership and Board of Directors.As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. He will continue as CEO for a period to support a smooth transition to new leadership. A search for Lars Fruergaard Jørgensen's successor is ongoing, and an announcement will be made in due course. In connection with the change, Lars Rebien...
Nasdaq GlobeNewswire
16/05/2025

Brainomix Presents Robust Validation of Its FDA-Cleared e-Lung Technology from…

Dr Susanne Stowasser, Associate Head of Medicine Therapeutic Area Inflammation at Boehringer Ingelheim said, "As part of our purpose of Transforming Lives for Generations at Boehringer, we seek collaborations to create value for patients. The imaging data presented at ATS from our INBUILD clinical trial in patients with progressive pulmonary fibrosis are part of a collaboration with Brainomix and others to advance the development of imaging biomarkers for better prognostication and…
PR Newswire
16/05/2025

Catherine Maree Holliday from Switzerland Selected as Finalist for Aster…

Founder of the Centre for Community-Driven Response, Catherine is the architect of PEEK—one of the world's largest patient experience databases. Her telehealth-led nursing framework, piloted in Australia and adapted for crisis regions, has transformed chronic and rare disease management in both developed and resource-limited settings. She has collaborated extensively with WHO, GAVI, and global patient networks to reshape health systems from the ground up. Founder of the Centre for...
PR Newswire
16/05/2025

From Affordable Premiums to Holistic Care, Policybazaar Unveils Comprehensive…

An increasing number of NRIs are opting for health insurance in India, not just for their families but also for themselves. This is because India offers an attractive value proposition. Health insurance premiums are at least 35% lower than in countries like the USA, Canada, Gulf nations, or Europe. Additionally, medical procedures, medicines, and consultations in India cost 70% to 90% less than in most Western countries, making high-quality care accessible at a fraction of the cost. An...
PR Newswire
16/05/2025

Genome & Company's Skincare Brand UIQ Expands into North America with Official…

Through its dedicated Amazon brand store, UIQ now offers signature products including Biome Barrier Cream Mist (100ml) and Biome Barrier Collagen Firming Cleansing Balm (100ml). These hero products—part of the Biome Barrier, Biome Remedy, and Biome C collections—exemplify the brand's commitment to science-backed, targeted skincare solutions. Notably, the Biome Barrier Cream Mist was awarded the Amazon's Choice badge shortly after launch, in recognition of its superior quality, user reviews, and…
PR Newswire
16/05/2025

Nordic Bioscience launches novel Endotrophin assay

NordicEndotrophin™ joins nordicPRO-C6™ and nordicPRO-C3™ (in-house versions of the FDA-supported PRO-C6 and CE approved PRO-C3 assays) to deliver a one-stop solution for assessing the fibro-inflammatory axis in chronic diseases, including cardiovascular, metabolic, renal and more. Following PRO-C3's recent deployment on Roche IVD platforms, the new Endotrophin assay strengthens risk stratification and pharmacodynamic monitoring. NordicEndotrophin™ joins nordicPRO-C6™ and nordicPRO-C3™…
PR Newswire
16/05/2025

Oxurion kondigt de ondertekening aan van een bindende overeenkomst tot overname…

Leuven, BELGIË – 16 mei 2025 om 8:30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf dat zich toelegt op de ontwikkeling van innovatieve therapieën, kondigt de ondertekening aan van een bindende overeenkomst voor de overname van 72% van het aandelenkapitaal van Axiodis CRO via zijn volledig in Frankrijk gevestigde dochteronderneming, Oxurion France…
Actusnews Wire
16/05/2025

Oxurion announces the signing of a binding agreement to acquire French…

Louvain, BELGIUM – May 16, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company focused on the development of innovative therapies, announces the signing of a binding agreement to acquire 72% of the share capital of Axiodis CRO through its wholly owned French subsidiary, Oxurion France…
Actusnews Wire
16/05/2025

ZINZINO AB (PUBL.): Zinzino announces China as the next step in its global…

"China's dynamic market and increasing health consciousness align perfectly with Zinzino's vision of personalized wellness," says Dag Bergheim Pettersen, CEO of Zinzino. "Our expansion into China is a strategic move to meet the growing demand for scientifically-backed, individualized health solutions." " China'sdynamic market and increasing health consciousness align perfectly with Zinzino's vision of personalized wellness," saysDag Bergheim Pettersen, CEO of…
PR Newswire
16/05/2025

Amorepacific and Johns Hopkins School of Medicine's Joint Research Program…

NBRI (New Beauty Research Initiative) is a collaborative research program that Amorepacific has maintained with the Department of Dermatology at Johns Hopkins School of Medicine since 2022. The two organizations conduct multifaceted research cooperation on skin aging. At this year's SID meeting, NBRI program participants Professor Anna Chien's research team presented the efficacy of Amorepacific's bio-flavonoid ingredient, RE.D Flavonoid, and Professor Martin Alphonse's research team presented…
PR Newswire
16/05/2025

ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic…

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal interstitial lung disease characterized by fibrotic remodeling of lung tissue, ultimately leading to respiratory failure, with a median survival period of only 2–5 years after diagnosis. Current therapeutics including pirfenidone and nintedanib have been available for years, however, with limited efficacy, significant adverse effects and poor long-term tolerability, highlighting the urgent need for novel and more…
PR Newswire
16/05/2025

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to…

Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company's branded franchises, stabilization of the company's generics business, focus on debt reduction and resolution of various legal liabilities https://ratings.moodys.com/ratings-news/443085 .“This is a testament to the consistent performance of Teva as a result of the company's Pivot to Growth strategy,” said Eli Kalif, Chief Financial Officer, Teva Pharmaceuticals. “This...
Nasdaq GlobeNewswire
16/05/2025

Eosinophilic Esophagitis Market Set to Surge as New Research Unveils…

Current eosinophilic esophagitis treatment guidelines include dietary modifications, medications, and endoscopic procedures. Among pharmacological options, proton pump inhibitors (PPIs) and corticosteroids are commonly used, though they are frequently associated with high relapse rates. The market holds limited approved eosinophilic esophagitis medications such as DUPIXENT (dupilumab) and JORVEZA (budesonide). Current eosinophilic esophagitis treatment guidelines include dietary…
PR Newswire
15/05/2025

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the…

Key Takeaways from the Cushing's Disease Market Report Key Takeaways from the Cushing's Disease Market Report Discover which therapies are expected to grab the major Cushing's disease market share @Cushing's Disease Market Report Cushing's Disease Overview Cushing's disease is a rare but serious endocrine disorder caused by a pituitary tumor that triggers excessive cortisol production. It presents with a variety of symptoms such as weight gain, fatigue, mood disturbances,...
PR Newswire
15/05/2025

Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with New Concentration

"Hospital pharmacists and healthcare providers are working harder than ever, and we are committed to supporting them with ready-to-use medicines that help reduce complexity and streamline operations so they can focus on what matters most—patient care," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions and Generics. "With this new ADRENALIN® premixed bag concentration, plus the additional concentrations in our pipeline, we are proud to offer…
PR Newswire
15/05/2025

Combined General Meeting of June 11, 2025

Combined General Meeting of June 11, 2025Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “ Company ”), will hold its Combined General Meeting (the “ General Meeting ”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company's headquarters located at IRO Building, 107 Avenue de la République, 92320...
Nasdaq GlobeNewswire
15/05/2025

Philips successfully prices offering of Notes for EUR 1 billion to be used for…

Amsterdam, the Netherlands – Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program.The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any Eligible Projects as defined inPhilips'...
Nasdaq GlobeNewswire
15/05/2025

Bulletin from the Annual General Meeting of Implantica AG

The general meeting resolved to carry forward the net loss for the financial year 2024 in accordance with the adopted balance sheet and to no payment of dividend. The general meeting resolved to carry forward the net loss for the financial year 2024 in accordance with the adopted balance sheet and to no payment of dividend. The general meeting resolved to discharge the members of the board of directors, the executive management and the auditors from liability for their services in the...
PR Newswire
15/05/2025

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial HighlightsIncome Statement Cosmos Health delivered...
Nasdaq GlobeNewswire
15/05/2025

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of €2,452,461,656 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
15/05/2025
Altri  Comunicati